What is NanobacTX?

NanobacTX is a patented non-prescription oral nanobiotic compound shown in published cardiology studies to help improve cardiovascular health and lipid profiles. Our published IRB-Monitored, peer-reviewed cardiology clinical trial results show that NanobacTX helps improve vascular health, heart health and increases exercise ability. NanobacTX  can help improve cardiovascular function, coronary blood flow and vascular flexibility. NanobacTX should be taken for 6-12 months of nightly treatment of 8 capsules/night. Thereafter, a maintenance program dosage of 1-2 capsules per night is required for continued benefit. One bottle consists of 240 patented capsules (1 month supply). Continue scrolling down to read the published research...

An Important Independent Summary of Our Scientific Research & Clinical Studies: Anton Kutikhin, PhD in The International Journal of NanoMedicine  "The Role of CNPs in Biology & Medicine"

(Please note that for publishing purposes, our Nanobiotics were referred-to as comET as a generic name and not our actual tradenames of NanobacTX & Urobac. Scientific publications allow only the use of generic names and not trademark names.)

Published Science & Clinical Studies:

1. Maniscalco, B.S., NanobacTX Cardiology Study. Journal of Pathophysiology.11(2): 95-101.

2. Puskas, L. G., L. Tiszlavicz, Zs Razga, L. Torday, T. Krenacs, J. G Papp.
Detection of nanobacteria-like particles in human atherosclerotic plaques. Acta Biologica Hungarica56 (3-4):

3. Jelic T. M., A. M. Malas, S. S. Groves, B. Jin, P. F. Mellen, G. Osborne, R. Roque, J. G. Rosencrance, and H. H. Chang. Nanobacteria-caused mitral valve calciphylaxis in a man with diabetic renal failure.South Med J.Feb; 97 (2): 194- 198.Click here to view study

4. Lieske J. C., V. Kumar, G. Farell-Baril, S. Yu, J. E. Charlesworth, E. Rzewusk-Lech, P. LaBreche, S. R. Severson, and V. M. Miller. Mayo Clinic.Detection and propagation of calcified nanostructures from human aneurysm.J Am Coll Cardiol Abstracts Book.1059-13: 13A.Click here to view study

5. Miller, V. M., G. Rodgers, J. A. Charlesworth, B. Kirkland, S. R. Severson, T. E. Rasmussen, M. Yagubyan, J. C. Rodgers, F. R Cockerill, III, R. L. Folk, V. Kumar, G. Farell-Baril, J. C. Lieske. MAYO CLINIC. Evidence of nanobacterial-like structures in human calcified arteries and cardiac valves. Am J Physiol Heart Circ Physiol.287 (3):

6. Kajander, E O.Nanobacteria do exist and actively participate in the calcification of arterial plaque.Townsend Letter 234:80-82.Click here to view study

7. Ciftcioglu, N., M. A. Miller-Hjelle. J. T. Hjelle and E. O. Kajander. Inhibition of Nanobacteria as measured by a modified microdilution method.Antimicrob Agents Chemother.46: 2077-2086.Click here to view study

8. Kajander, E. O., K. Aho and V. Segal. Apatite biofilm forming agent: nanobacteria as a model system for biomineralization and biological standard for noa, a preliminary study.Proceedings of the 2nd International Conference on Near-Field Optical analysis. Houston, Texas.Click here to view study

9. Rasmussen, T. E., B. L. Kirkland, J. Charlesworth, et al.Electron microscope and immunological evidence of nanobacteria in calcified carotid arteries, aortic aneurysms and cardiac valves.J Am Coll Cardiol Abstracts Book.1009-79: 206A.Click here to view study

10. Ciftcioglu, N., V. Ciftcioglu, H. Vali, E. Turcott, E. O. Kajander. Sedimentary rocks in our mouth: dental pulp stones made by nanobacteria. Proc. SPIE.3441: 130-135.Click here to view study

Studies specific to Pathological Calcification & Nanobacteria:

1. Kajander EO; Nanobacteria - propagating calcifying nanoparticles. Lett Appl Microbiol. 2006 Jun; 42(6):549-52. Click here to view study

2. Tsurumoto T., T. Matsumoto, A. Yonekura, and H. Shindo; Nanobacteria in Human Arthritic Synovial Fluids. Journal of Proteome Research. ASAP Article 10.1021/pr050450w S1535-3893(05)00450-1 [April 8, 2006] American Chemical Click here to view study

3. Ciftioglu NNanobacteria-Discovery of a new form of life. Horizons 2006 March 31: 7-8.

4. Sommer, AP; Wichramasinghe, NC. Functions and Possible Provenance of Primordial Proteins-Part II: Microorganism Aggregation in Clouds Triggered by Climate Change. Journal of Proteome Research. 4: 180-184, 2005. Click here to view study

5. Sommer, AP; Pretorius, AM; Kajander, EO and Oron, U. Biomineralization induced by stressed nanobacteria. Crystal Growth & Design. 2004. (1): 45-46. Click here to view study

6. Wang, XJ, et al. 2004. The detection of nanobacteria infection in serum of healthy Chinese people. Zhonghua Liu Xing Bing Xue Za Zhi. 25(6):494-4. Click here to view study

7. Wilk, IG, Martirosian, KZ; Mikrobiologii, S. A. Medycznei, Khatowice. 2004. Nanobacteria microbiological characteristics. Postepy Hig Med Dosw (online), 2004; 58: 60-64. Click here to view study

8. Aho K, Kajander EO. 2003. Detection of Novel Nanoorganisms .J Clin Microbiol. 41(7): 3460-3461. Click here to view study

9. Barr SC, Linke, SE, et al. 2003. Detection of biofilms formation and nanobacteria under long-term cell culture conditions in serum samples of cattle, goats, cats and dogs. Am J Vet Res. 64(2):176-182.

10. Miller-Hjelle, MA; Hjelle, JT; Ciftcioglu, N; Kajander, EO. 2003. Nanobacteria: methods for growth and identification of this recently discovered calciferous agent. Rapid Analytical Microbiology. The chemistry and physics of microbial identification. Ed. . Olson. PDA, Bethesda, MD, USA. 297-312. Click here to view study

11. Sommer, AP, McKay, DS; Ciftcioglu, N; Oron, U; Mester, AR; Kajander, EO. 2003. Living nanovesicles-chemical and physical survival strategies of primordial biosystems. Perspectives, J. Proteome Res. 2:441-443. Click here to view study

12. Ciftcioglu, N., Miller-Hjelle, MA; Hjelle, JT; Kajander, EO. 2002. Inhibition of nanobacteria as measured by a modified microdilution method. Antimicrob Agents Chemother. 46: 2077-2086. Click here to view study

13. Kajander, EO; Aho, K; Segal, V. 2002. Apatite biofilm forming agent: nanobacteria as a model system for biomineralization and biological standard for noa, a preliminary study. Proceedings of the 2nd International Conference on Near-Field Optical analysis: Photodynamic Therapy & Photobiology Effects. Houston, TX. Click here to view study

14. Sommer AP, Hassinen, HI; Kajander, EO. 2002. Light-induced replication of nanobacteria: a preliminary report. J Clin Laser Med Surg.20(5)

15. Sommer, A. P., U. Oron, E. O. Kajander and A. R. Mester. 2002. Stressed cells survive better with light. J. Proteome Res.1:475. Click here to view study

16. Breitschwerdt, EB, Sushama, S, Cannedy, A, Hancock, SI, Bradley, JM. 2001. Infection with Bartonella weissii and Detection of Nanobacteria Antigens in a North Carolina Beef Herd Journal of Clinical Microbiology. 879-882. Click here to view study

17. Vali, H; McKee, DM; Ciftcioglu, N; Kajander, EO; Sears, SK; et al. 2001. Nanoforms: a new type of protein-associated mineralization. Geochim.Cosmochim. Acta. 65:63-74. Click here to view study

18. Ciftcioglu, N; Kajander, EO. 2000. Nanobacterial Growth Factors Proc. SPIE. 3755: 113-119. Click here to view study

19. Kajander, EO; Ciftcioglu, N. 2000. Nanobacteria as Extremophiles Proc. SPIE. 3755: 106-112. Click here to view study

20. Vainshtein MB; Kudriashova, EB. 2000. About Nanobacteria. Mikrobiologiia (Russian). 69(2):163-174.

21. Ciftcioglu, N. 1999. Microbial Presence vs Pathogenicity: Pleomorphic Microbes in Health and Disease. Proceedings of the first annual symposium held June 18-19. Edited by: Gitte S. Jensen Ph.D. Holger N.I.S. Inc.; 49-53. Click here to view study

22. Kajander, EO; Bjorklund, M; Ciftcioglu, N. 1999. Nanobacteria and Man: Enigmatic Microorganisms and Life in Extreme Environments. Eds.J. Seckbach, Kluwer (the Netherlands). 195-204. Click here to view study

23. Kajander, EO. 1999. Nanobacteria: Pleomorphic microbes in health and disease. Proceedings of the first annual symposium held June 18-19, 1999. Edited by: Gitte S. Jensen Ph.D. Holger N.I.S. Inc. Hudson, Quebec; 43-48. Click here to view study

24. Kajander, EO; Heinonen, T; Kuronen, I; Luoto, K; Ciftcioglu, N. 1999. A New Problem for Sterile Filtration: Nanobacteria. Proceedings, WorldPharm. 99, October 26-28, 1999, Philadelphia. Advanstar Communications, Cleveland, OH. Pp. 243-252. Click here to view study

25. Kajander, EO; T. Heinonen, I. Kuronen, K. Luoto, N. Ciftcioglu. Nanobacteria, mycoplasma and bacterial l-forms; problems for sterile filtration. 30th R3. Nordic Contamination Control Symposium.Helsinki, Finland. Click here to view study

26. Southam, G., R. Donald. 1999. A structural comparison of bacterial microfossils vs. nanobacteria and nanofossils. Earth-Science Reviews.48 (4): 251-264.

27. Wainwright, M. 1999. Nanobacteria and associated elementary bodies in humans. Microbiology. 145: 2623-2624. Click here to view study

28. Bjorklund, M., N. Ciftcioglu, E. O. Kajander. 1998. Extraordinary survival of nanobacteria under extreme conditions. Proc. SPIE. 3441: 123-129. Click here to view study

29. Carson, DA. 1998. An Infectious Origin of Extraskeletal Calcification. PNAS.95: 7846-7847. Click here to view study

30. Ciftcioglu, N., E. O. Kajander. 1998. Interaction of nanobacteria with cultured mammalian cells. Pathophysiology. 4: 259-270. Click here to view study

31. Ciftcioglu, N., M. Bjorklund, E. O. Kajander. 1998. Stone formation and calcification by nanobacteria in human body. Proc. SPIE.3441: 105-111. Click here to view study

32. Kajander, E. O., M. Bjorklund, N. Ciftcioglu. 1998. Suggestions from observations on nanobacteria isolated from blood. Size limits of very small microorganisms: proceedings of a workshop, steering group on astrobiology of the Ciftcioglu, N., M. Bjorklund, K. Kuorikoski, K. Click here to view study

33. Kajander, E. O., N. Ciftcioglu, M. Bjorklund. 1998. Mineralization by nanobacteria Proc. SPIE. 3441: 86-94. Click here to view study

34. Kajander, E. O., N. Ciftcioglu. 1998. Nanobacteria: An alternative mechanism for pathogenic intra- and extracellular calcification and stone formation Proc. Natl. Acad. Sci. USA 95: 8274-8279. Click here to view study

35. Akerman, K. K., J. T. Kuikka, N. Ciftcioglu, J. Parkkinen, K. A. Bergstrom, I. Kuronen, and E. O. Kajander. 1997. Radiolabeling and in vivo distribution of nanobacteria in rabbit. Proc. SPIE. 3111: 436-442. Click here to view study

36. Ciftcioglu, N., A. Pelttari, E. O. Kajander. 1997. Extraordinary growth phases of nanobacteria isolated from mammalian blood. Proc. SPIE. 3111: 429-435. Click here to view study

37. Cifcioglu, N., I. Kuronen, K. Akerman, E. Hiltunen, J. Laukkanen, E.O. Kajander, et al. 1997.A new potential threat in antigen and antibody products: nanobacteria. Cold spring harbor laboratory. Vaccines 97. 99-103. Click here to view study

38. Kajander, E. O., I. Kuronen; K. Akerman, A. Pelttari, N. Ciftcioglu. 1997. Nanobacteria from blood, the smallest culturable autonomously replicating agent on earth. Proc. SPIE. 3111: 420-428. Click here to view study

39. Kajander, E. O., E. Tahvanainen, I. Kuronen, N. Ciftcioglu. 1994. Comparison of staphylococci and novel bacteria-like particles from blood. Zbl. Bakt. (Suppl.) 26: 147-149. Click here to view study

40. Akerman, K. K., I. Kuronen, and E. O. Kajander. 1993. Scanning Electron Microscopy of Nanobacteria: Novel Biofilm Producing Organisms in Blood. Scanning. 15 (Suppl.) 3:90-91. Click here to view study